These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 14500300)

  • 1. Radiographic long bone appearance in a child administered cyclical pamidronate.
    Davies JH; Gregory JW
    Arch Dis Child; 2003 Oct; 88(10):854. PubMed ID: 14500300
    [No Abstract]   [Full Text] [Related]  

  • 2. Images in clinical medicine. Radiographic zebra lines from cyclical pamidronate therapy.
    Sarraf KM
    N Engl J Med; 2011 Jul; 365(3):e5. PubMed ID: 21774705
    [No Abstract]   [Full Text] [Related]  

  • 3. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
    Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
    Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteogenesis imperfecta and intravenous pamidronate.
    Banerjee I; Shortland GJ; Evans WD; Gregory JW
    Arch Dis Child; 2002 Dec; 87(6):562-3. PubMed ID: 12456578
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis.
    Onwuneme C; Abdalla K; Cassidy N; Hensey O; Ryan S
    Arch Dis Child; 2007 Dec; 92(12):1087. PubMed ID: 18032639
    [No Abstract]   [Full Text] [Related]  

  • 7. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
    Choi JH; Shin YL; Yoo HW
    J Korean Med Sci; 2007 Apr; 22(2):209-12. PubMed ID: 17449925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of denosumab on the growing skeleton in osteogenesis imperfecta.
    Hoyer-Kuhn H; Semler O; Schoenau E
    J Clin Endocrinol Metab; 2014 Nov; 99(11):3954-5. PubMed ID: 25148238
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclic bisphosphonate therapy in osteogenesis imperfecta type V.
    Fleming F; Woodhead HJ; Briody JN; Hall J; Cowell CT; Ault J; Kozlowski K; Sillence DO
    J Paediatr Child Health; 2005 Mar; 41(3):147-51. PubMed ID: 15790328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Zebra bones after bisphosphonate treatment].
    Füeßl HS
    MMW Fortschr Med; 2015 Mar; 157(5):38. PubMed ID: 26015008
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravenous pamidronate treatment in osteogenesis imperfecta.
    Bembi B; Parma A; Bottega M; Ceschel S; Zanatta M; Martini C; Ciana G
    J Pediatr; 1997 Oct; 131(4):622-5. PubMed ID: 9386671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
    Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
    Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F; Munns C; Land C; Glorieux FH
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta.
    Land C; Rauch F; Glorieux FH
    J Bone Miner Res; 2006 Mar; 21(3):374-9. PubMed ID: 16491284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta.
    Amarasena S; Lekamwasam S; Jayawardena P
    Ceylon Med J; 2005 Sep; 50(3):137-8. PubMed ID: 16252586
    [No Abstract]   [Full Text] [Related]  

  • 16. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
    Plotkin H; Rauch F; Bishop NJ; Montpetit K; Ruck-Gibis J; Travers R; Glorieux FH
    J Clin Endocrinol Metab; 2000 May; 85(5):1846-50. PubMed ID: 10843163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamidronate lines.
    Srinivasan R
    Indian Pediatr; 2005 Sep; 42(9):959-60. PubMed ID: 16208065
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.
    Rauch F; Cornibert S; Cheung M; Glorieux FH
    Bone; 2007 Apr; 40(4):821-7. PubMed ID: 17223617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
    N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.